



Attorney's Docket No.: 10274-006002 / D011 CIP2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Wallner et al. Art Unit : 1644
Serial No. : 09/730,465 Examiner : P. Gambel
Filed : December 5, 2000
Title : METHOD OF PROPHYLAXIS OR TREATMENT OF ANTIGEN PRESENTING CELL DRIVEN SKIN CONDITIONS USING INHIBITORS OF THE CD2/LFA-3 INTERACTION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER UNDER 37 CFR §§3.73(b) AND 1.321(b)

Pursuant to 37 CFR §3.73(b), BIOGEN, INC., a corporation, and THE REGENTS OF THE UNIVERSITY OF MICHIGAN, a corporation, certify that together, they are the assignees of the entire right, title, and interest in the above application by virtue of:

Assignments from the inventors of the patent application identified above.

The assignment to Biogen, Inc. was recorded in the Patent and Trademark Office at Reel 7584, Frame 0554-0555 on June 6, 1995. The assignment to The Regents of the University of Michigan was recorded in the Patent and Trademark Office at Reel 7586, Frame 0417-0418 on June 6, 1995.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

| 07/08/2003 ZJUHAR1 00000120 061050 09730465
01 FC:1814 110.00 DA

Date of Deposit

Signature

Typed or Printed Name of Person Signing Certificate

Applicant : Wallner et al.
Serial No. : 09/730,465
Filed : December 5, 2000
Page : 2 of 3

Attorney's Docket No.: 10274-006002 / D011 CIP2

The undersigned have reviewed all the documents in the chain of title of the above-identified application and to the best of undersigned's knowledge and belief, title is in the assignees identified above.

Each undersigned (whose title is supplied below) is empowered to act on behalf of the indicated assignee.

Pursuant to 37 CFR §1.321(b), and to obviate a double patenting rejection, the assignee identified above hereby waives and disclaims the terminal portion of the term of the entire patent to be granted upon the above identified application subsequent to the expiration date of U.S. Patent No. 6,162,432, whereby the patent granted on this application will expire no later than the expiration date of Patent No. 6,162,432, provided that any patent granted on the above identified application shall be enforceable only for and during such period that it is commonly owned with U.S. Patent No. 6,162,432.

The assignees identified above do not disclaim any terminal part of any patent granted on the above identified application prior to the expiration date of the full statutory term of U.S. Patent No. 6,162,432 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title as stated above.

Assignees herein do not disclaim or otherwise affect any part of U.S. Patent No. 6,162,432.

This disclaimer runs with any patent granted on the above application and is binding upon the grantee, its successors or assigns.

Enclosed is a check for \$110 for the required fee pursuant to 37 CFR §1.20(d).

*[The PTO did not receive the following
from(s) A CLOCK OF \$110.00]*

Applicant : Wallner et al.
Serial No. : 09/730,465
Filed : December 5, 2000
Page : 3 of 3

Attorney's Docket No.: 10274-006002 / D011 CIP2

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

BIOGEN, INC.

Name: _____
Title: _____
Date: _____

THE REGENTS OF THE UNIVERSITY OF
MICHIGAN

Name: _____
Title: _____
Date: _____

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906